Tenders of Aok Rheinland Pfalz Saarland Die Gesundheitskasse
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient Lenograstim (l03aa10) within the framework of a so-called open-house model.
Closing Date30 Nov 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicines with the active ingredient glatiramer acetate (l03ax13), 40mg pre-filled syringes (open-house model)
Closing Date30 Nov 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient buserelin (l02ae01) within the framework of a so-called open-house model.
Closing Date30 Nov 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredients Lopinavir and Ritonavir (j05ar10) within the framework of a so-called open-house model.
Closing Date30 Nov 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient fusidic acid (d06ax01) as part of a so-called open-house model.
Closing Date30 Nov 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient Ambrisentan (c02kx02) within the framework of a so-called open-house model.
Closing Date30 Nov 2025
Tender AmountRefer Documents
251-260 of 294 active Tenders